Progen of Brisbane, Australia, said it has finished enrolling
14 patients in a phase-1b trial of PI-88 for advanced stage cancer of
various kinds. The agent, an angiogenesis inhibitor, is also aimed at
preventing metastasis by shutting down production of the
enzyme heparanase.
